Every material Form 8-K Claritev Corp has filed with the SEC since August 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Claritev Corporation increased its board from 11 to 12 directors and appointed Jennifer Main, a former CMS Chief Operating Officer and TARP chief financial officer, to fill the new seat effective October 15, 2026. Main also joined the Audit Committee, replacing Jason Kap on that committee. The filing describes a board addition rather than a change in financial results or guidance.
Board increased from 11 to 12 directors; Jennifer Main appointed as Class II director effective October 15, 2026
Main joins the Audit Committee; Jason Kap ceased serving on the Audit Committee
Main previously served as Chief Operating Officer of CMS from 2018 to 2021 and as Chief Financial Officer of Amalgam Rx from 2021 to 2026
Main will receive non-employee director compensation under the company's existing policy and sign the standard indemnification agreement
Claritev Corporation appointed Ben Letham as a Class I director effective September 14, 2026, filling the seat left vacant by the passing of John Prince, and added him to the Board's Risk Committee. The filing discloses no financial results, guidance, or transaction terms, so the change is a board composition update.
Ben Letham appointed to the Board as a Class I director effective September 14, 2026.
Letham also joined the Board's Risk Committee, effective the same date.
Letham is a research scientist at Meta focused on AI and optimization systems; he will receive non-employee director compensation under the Company's existing policy.
Claritev reported second-quarter 2026 revenue of $257.5 million, up 6.6% from a year earlier, and a net loss of $59.2 million, narrower than the $62.6 million loss in Q2 2025. The company raised its full-year 2026 guidance for revenue, Adjusted EBITDA and free cash flow, which matters to shareholders because it points to higher expected results for the year.
Q2 2026 revenue was $257.5 million, up from $241.6 million in Q2 2025.
Net loss was $59.2 million in Q2 2026, compared with $62.6 million in Q2 2025.
Adjusted EBITDA rose 1.1% to $155.8 million, though the margin fell to 60.5% from 63.8%.
Full-year 2026 revenue guidance rose to $1 billion to $1.02 billion from $985 million to $1 billion, and Adjusted EBITDA guidance rose to $610 million to $620 million from $605 million to $615 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Claritev Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →